Chiasma, Inc. (NASDAQ:CHMA) will be hosting a conference call at 5:00 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.chiasmapharma.com
Earnings Expectation
Chiasma, Inc. is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, CHMA is expected to report 3Q20 loss of $ 0.39 per share. For the full year, analysts anticipate top line of $ 1.64 million, while looking forward to loss of $ 1.66 per share bottom line.
Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the bodys production of excess growth hormone. Chiasma, Inc.
